The purpose of this study is to evaluate the effects of the addition of SG301 injection to pomalidomide and dexamethasone in subjects with relapsed or refractory multiple myeloma.
Understand and voluntarily sign the informed consent form (ICF).
Males and females aged 18-75 years (inclusive)
Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0, 1 or 2
Expected survival time of ≥3 months.
Primary refractory multiple myeloma defined as participants who had never achieved at least a minimal response (MR) with any treatment during the disease course.
Bone independent extramedullary disease at screening.
Subjects who are primary refractory to a prior CD38 monoclonal antibody therapy.
Previous exposure to pomalidomide.